Sugars control the cell!
Sugar biology is more powerful than most researchers expect. One modification in particular — the addition of a single sugar called O-GlcNAc to serine and threonine residues on proteins — sits at the center of some of the most consequential metabolic decisions a cell makes.
O-GlcNAc modification is not a peripheral regulatory event. It directly shapes how cells sense nutrients, how tumors sustain growth, and how insulin signaling breaks down in type 2 diabetes. Understanding it is one of the most important open problems in metabolic disease research right now.
This article explains what O-GlcNAc modification does to cell metabolism, why it matters in cancer and diabetes specifically, and why we make precision chemical tools to study this critical sugar in live cell settings.
What Is O-GlcNAc Modification?
O-GlcNAc (O-linked N-acetylglucosamine) is a monosaccharide added post-translationally to proteins inside the cell. Unlike N-glycosylation, which occurs in the endoplasmic reticulum and Golgi, O-GlcNAcylation happens in the cytoplasm, nucleus, and mitochondria. That location matters: it puts this modification directly in contact with signaling proteins, transcription factors, and metabolic enzymes.
The modification is dynamic. It cycles on and off proteins in response to nutrient availability, stress, and cellular context. This makes it a real-time sensor of metabolic state, not a static structural tag.
The substrate for O-GlcNAc is UDP-GlcNAc, the end product of the hexosamine biosynthetic pathway (HBP). The HBP integrates inputs from glucose, glutamine, acetyl-CoA, and UTP — meaning O-GlcNAc levels reflect the overall nutritional status of the cell. When glucose flux is high, UDP-GlcNAc rises, and more proteins get O-GlcNAcylated. The cell is, in effect, reading its own sugar supply through this modification.
The Enzymes Behind the Switch: OGT and OGA
Two enzymes control O-GlcNAc cycling. OGT (O-GlcNAc transferase) adds the modification. OGA (O-GlcNAcase) removes it.
OGT is a single gene in mammals, yet it modifies thousands of protein substrates. It does this with remarkable selectivity, guided by its TPR domain and by interacting proteins that direct it to specific targets. Dysregulation of OGT is documented in multiple cancers and in insulin-resistant tissues.
OGA is the eraser. Inhibiting OGA raises global O-GlcNAc levels and has been explored as a therapeutic strategy in neurodegeneration, where tau hyperphosphorylation competes with O-GlcNAcylation at overlapping sites. The same competitive relationship between phosphorylation and O-GlcNAcylation appears in metabolic signaling pathways relevant to diabetes.
Understanding how OGT selects substrates, and how that selectivity shifts in disease states, is one of the central questions driving chemical biology research in this space.
How O-GlcNAc Rewires Metabolism in Cancer
Cancer cells reprogram their metabolism to support rapid proliferation. The Warburg effect — preferential use of glycolysis even in the presence of oxygen — is one well-known example. O-GlcNAc modification is woven into this reprogramming at multiple levels.
Elevated O-GlcNAcylation is a consistent feature of many tumor types. Several mechanisms explain why:
- Glucose flux drives HBP activity. Tumors consume glucose at high rates, which raises UDP-GlcNAc and pushes more O-GlcNAcylation onto proteins.
- O-GlcNAc stabilizes oncoproteins. Modification of proteins like c-Myc and HIF-1α at specific sites protects them from proteasomal degradation, sustaining pro-growth transcriptional programs.
- Metabolic enzyme activity shifts. O-GlcNAcylation of glycolytic enzymes including phosphofructokinase-1 (PFK1) alters flux through glycolysis, redirecting intermediates toward biosynthetic pathways that support nucleotide and lipid synthesis.
- Mitochondrial function is altered. O-GlcNAcylation of electron transport chain components and mitochondrial proteins affects oxidative phosphorylation, contributing to the metabolic flexibility that makes tumors resilient.
- Cancer Stem-Like Cells (CSCs). We found that enhanced O-GlcNAcylation directly reprogram breast tissue cells into cancer stem-like cells…the “seed” that allows cancers to start, then to metastasize through the body, and even to resist chemotherapy to come back as recurrent cancer! Check out our paper, here: https://pubmed.ncbi.nlm.nih.gov/37231419/
Taken together, O-GlcNAc modification does not simply respond to cancer metabolism — it actively maintains it and allows it to spread faster in high glucose conditions like metabolic disease (diabetes, obesity, polycystic ovary syndrome). That makes OGT a compelling target, and it makes the ability to map O-GlcNAc sites on specific proteins in tumor cells a high-priority methodological need.
The Role of O-GlcNAc in Diabetes and Insulin Signaling
In type 2 diabetes, chronic nutrient excess drives sustained elevation of O-GlcNAc levels in metabolic tissues. This has direct consequences for insulin signaling.
Insulin receptor substrate proteins (IRS-1 and IRS-2) are O-GlcNAcylated at sites that overlap with activating phosphorylation sites. When O-GlcNAc occupies these positions, the downstream PI3K-Akt pathway is blunted. The cell becomes less responsive to insulin — a molecular description of insulin resistance.
The relationship between O-GlcNAc and glucose toxicity is also relevant to pancreatic beta cells. Chronic hyperglycemia elevates HBP flux in beta cells, increasing O-GlcNAcylation of transcription factors that regulate insulin gene expression and beta cell survival. Over time, this contributes to beta cell dysfunction.
This creates a feedback loop: high glucose raises O-GlcNAc, O-GlcNAc impairs insulin signaling and beta cell function, which worsens glucose control, which raises O-GlcNAc further. Breaking this loop requires understanding exactly which proteins are modified, at which sites, and how that changes in the transition from insulin resistance to overt type 2 diabetes.
Why O-GlcNAc Is Hard to Study — and How Chemical Tools Help
O-GlcNAc research faces a persistent methodological challenge. The modification is substoichiometric on most proteins, labile under standard proteomics conditions, and competes with phosphorylation at overlapping residues. Standard antibody-based detection is limited in site-specificity and coverage.
Chemical biology tools address these limitations directly. Metabolic labeling strategies using unnatural sugar analogs — including GalNAz and Ac4GlcNAz — allow researchers to tag O-GlcNAcylated proteins selectively and enrich them for mass spectrometry analysis. Bioorthogonal chemistry makes it possible to visualize O-GlcNAc dynamics in living cells without disrupting normal biology.
In the Fehl Lab, we design precisely this kind of chemical tool. We combine custom probe design, large datasets, and machine learning algorithms to identify which glycobiology pathways are most active in disease-relevant contexts, and to prioritize which protein-modification events are worth pursuing as targets. This approach lets us move from broad pathway observation to specific, testable hypotheses about how O-GlcNAc drives cancer and diabetes.
You’re in the right place to learn about our ongoing research…check out our Publications!
What This Means for Metabolic Disease Research
O-GlcNAc sits at the intersection of nutrient sensing, signal transduction, and gene regulation. That position makes it relevant not just to cancer and diabetes, but also to obesity and neurodegeneration — disease areas where metabolic dysregulation is a shared underlying mechanism.
For researchers working on metabolic reprogramming, O-GlcNAc is not a side story. It is a central regulatory axis that connects the cell’s sugar supply to its most consequential decisions about growth, survival, and stress response.
Mapping that axis precisely, and building tools that make it tractable, is work that matters for patients. We design those tools at the Fehl Lab. If you are working on related questions and want to explore collaboration, contact Charlie Fehl at Wayne State University’s Chemistry Department!
FAQs
What is O-GlcNAc modification?
O-GlcNAc modification is the addition of a single N-acetylglucosamine sugar to serine or threonine residues on intracellular proteins. It is dynamic, cycling on and off in response to nutrient availability, and it regulates a wide range of signaling and metabolic proteins.
How does O-GlcNAc affect cancer cell metabolism?
Elevated O-GlcNAcylation in cancer cells stabilizes oncoproteins, alters glycolytic enzyme activity, and supports biosynthetic pathways needed for rapid proliferation. High glucose consumption by tumors drives increased UDP-GlcNAc production, which sustains this elevated modification state. Stopping OGT activity with inhibitors is a proven way to slow down this proliferation, and importantly the cancer stem-like cell pathway we found in breast cancer tumors.
What is the connection between OGT enzyme activity and diabetes?
OGT modifies insulin receptor substrate proteins at sites that overlap with activating phosphorylation residues. When O-GlcNAc occupies these sites — as happens in chronic nutrient excess — insulin signaling through the PI3K-Akt pathway is reduced, contributing to insulin resistance. We think that OGT is an excellent target for restoring insulin sensitivity in diabetic patients.
Why is O-GlcNAc difficult to study with standard proteomics methods?
O-GlcNAc is substoichiometric on most target proteins, labile under typical mass spectrometry conditions, and competes with phosphorylation at overlapping sites. Standard antibody reagents lack the site-specificity needed to map modification events comprehensively across the proteome. Precision chemical tools can address this gap.
What chemical tools are used to study O-GlcNAc in living cells?
Metabolic labeling with unnatural sugar analogs such as our PhotoSugar analogs (light-controlled metabolic chemical reporters!), combined with bioorthogonal chemistry, allows selective tagging and enrichment of O-GlcNAcylated proteins. These approaches enable site-specific proteomics and real-time imaging of O-GlcNAc dynamics in live cells. Our GlycoID system is another cell-based platform that labels O-GlcNAc in live cells under physiologically neutral conditions!
Does O-GlcNAc modification play a role in neurodegeneration?
Yes. O-GlcNAcylation of tau protein competes with phosphorylation at overlapping sites. Reduced O-GlcNAc on tau is associated with hyperphosphorylation and aggregation on tau and alpha-synuclein, which are hallmarks of Alzheimer’s disease and Parkinson’s pathology, respectively. OGA inhibition has been explored as a strategy to restore this balance. Stay tuned for new chemical probes from the Fehl Lab that can potentially address this space.
How does the Fehl Lab approach O-GlcNAc research?
The Fehl Lab at Wayne State University’s Department of Chemistry designs custom chemical tools to study carbohydrate-linked proteins, including O-GlcNAcylated substrates, in metabolic disease contexts. The lab integrates machine learning with chemical biology to identify and target specific glycobiology pathways in cancer, diabetes, and other metabolic diseases. Learn more at fehl-lab.com.
